| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2016 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Immune Design Corp. | 4 | Q3 2015 | 100.0% |
View COLUMN GROUP L P's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Nurix Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 2,584,957 | 5.4% |
| IMMUNE DESIGN CORP. | February 19, 2019 | 3,161,942 | 6.6% |
View COLUMN GROUP L P's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-08 |
| SC 13D/A | 2024-04-05 |
| SC TO-T/A | 2024-04-05 |
| SC TO-T/A | 2024-03-22 |
| SC TO-T | 2024-03-08 |
| SC 13D/A | 2024-02-26 |
| SC TO-C | 2024-02-26 |
| SC 13D/A | 2023-12-29 |
| 4 | 2023-11-17 |
| 4 | 2023-11-17 |
View COLUMN GROUP L P's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.